Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: A randomized double-blind placebo-controlled pilot study

Fundamental and Clinical Pharmacology

Volumn 26, Issue 6, 2012, Pages 761-770

  Joyeux Faure, Marie ^a   Durand, Michel ^b   Bedague, Damien ^b   Protar, Daniel ^b   Incagnoli, Pascal ^b   Paris, Adeline ^b   Ribuot, Christophe ^a   Levy, Patrick ^a,b   Chavanon, Olivier ^a,b  

^a University Grenoble Alpes   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Cerebral protection; Erythropoietin; Myocardial protection

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; PLACEBO; PROTEIN S100B; RECOMBINANT ERYTHROPOIETIN; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOPULMONARY BYPASS; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG MEGADOSE; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; INFLAMMATION; MALE; NEUROPROTECTION; PILOT STUDY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CARDIOPULMONARY BYPASS; CYTOKINES; CYTOPROTECTION; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NERVE GROWTH FACTORS; PILOT PROJECTS; RECOMBINANT PROTEINS; REPERFUSION INJURY; S100 PROTEINS; TREATMENT OUTCOME; TROPONIN T;

EID: 84867997603     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00992.x     Document Type: Article

References (25)

1. Dunn C.J., Markham A. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Drugs (1996) 51 299-318.
2. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. (Maywood) (2003) 228 1-14.
3. Ng T., Marx G., Littlewood T., Macdougall I. Recombinant erythropoietin in clinical practice. Postgrad. Med. J. (2003) 79 367-376.
4. Joyeux-Faure M. Cellular protection by erythropoietin: new therapeutic implications? J. Pharmacol. Exp. Ther. (2007) 323 759-762.
5. Siren A.L., Knerlich F., Poser W., Gleiter C.H., Bruck W., Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. (2001) 101 271-276.
6. Bogoyevitch M.A. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc. Res. (2004) 63 208-216.
7. Brines M.L., Ghezzi P., Keenan S. et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl Acad. Sci. USA (2000) 97 10526-10531.
8. Ehrenreich H., Hasselblatt M., Dembowski C. et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. (2002) 8 495-505.
9. Joyeux-Faure M., Godin-Ribuot D., Ribuot C. Erythropoietin and myocardial protection: what's new? Fundam. Clin. Pharmacol. (2005) 19 439-446.
10. Joyeux-Faure M., Ramond A., Beguin P.C., Belaidi E., Godin-Ribuot D., Ribuot C. Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. Fundam. Clin. Pharmacol. (2006) 20 51-56.
11. Takeda S., Nakanishi K., Ikezaki H. et al. Cardiac marker responses to coronary artery bypass graft surgery with cardiopulmonary bypass and aortic cross-clamping. J. Cardiothorac. Vasc. Anesth. (2002) 16 421-425.
12. Crescenzi G., Cedrati V., Landoni G. et al. Cardiac biomarker release after CABG with different surgical techniques. J. Cardiothorac. Vasc. Anesth. (2004) 18 34-37.
13. Morimoto K., Mori T., Ishiguro S., Matsuda N., Hara Y., Kuroda H. Perioperative changes in plasma brain natriuretic peptide concentrations in patients undergoing cardiac surgery. Surg. Today (1998) 28 23-29.
14. Avidan M.S., Meehan N., Ponte J., El-Gamel A., Sherwood R.A. Changes in brain natriuretic peptide concentrations following open cardiac surgery with cardioplegic cardiac arrest. Clin. Chim. Acta (2001) 303 127-132.
15. Westaby S., Johnsson P., Parry A.J. et al. Serum S100 protein: a potential marker for cerebral events during cardiopulmonary bypass. Ann. Thorac. Surg. (1996) 61 88-92.
16. Ali M.S., Harmer M., Vaughan R. Serum S100 protein as a marker of cerebral damage during cardiac surgery. Br. J. Anaesth. (2000) 85 287-298.
17. Johnsson P., Backstrom M., Bergh C., Jonsson H., Luhrs C., Alling C. Increased S100B in blood after cardiac surgery is a powerful predictor of late mortality. Ann. Thorac. Surg. (2003) 75 162-168.
18. Kerbaul F., Collart F., Giorgi R. et al. Increased plasma levels of pro-brain natriuretic peptide in patients with cardiovascular complications following off-pump coronary artery surgery. Intensive Care Med. (2004) 30 1799-1806.
19. Murphy G.J., Angelini G.D. Side effects of cardiopulmonary bypass: what is the reality? J. Card. Surg. (2004) 19 481-488.
20. Laffey J.G., Boylan J.F., Cheng D.C. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology (2002) 97 215-252.
21. Poulsen T.D., Andersen L.W., Steinbruchel D., Gotze J.P., Jorgensen O.S., Olsen N.V. Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. J. Cardiothorac. Vasc. Anesth. (2009) 23 316-323.
22. Lipsic E., van der Meer P., Henning R.H. et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol. (2004) 44 473-479.
23. Mocini D., Muso P., Guendouz E. et al. Endogenous erythropoietin and a single bolus of 40, 000IU of epoetin alpha do not protect the heart from ischaemia-reperfusion injury during extracorporeal circulation for cardiac surgery. Perfusion (2008) 23 187-192.
24. Lipsic E., van der Meer P., Voors A.A. et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc. Drugs Ther. (2006) 20 135-141.
25. Haljan G., Maitland A., Buchan A. et al. The erythropoietin neuroprotective effect: assessment in CABG surgery (TENPEAKS): a randomized, double-blind, placebo controlled, proof-of-concept clinical trial. Stroke (2009) 40 2769-2775.